Atlas Compliance Blog

FDA Form 483 observations and Warning Letters keep pointing to the same root causes, data integrity lapses, weak quality systems (including CAPA and quality unit failures), inadequate process/equipment qualification, poor contamination control and environmental monitoring, incomplete stability and supplier controls, and documentation gaps. FY2024 shows increased inspection activity and an uptick in warning letters, driven […]

The FDA’s 2025 draft guidances for AI/ML in drug and device development mark the transition from exploratory policy signals to concrete, operational expectations. Key new elements include a risk-based “credibility” framework for AI used to support regulatory decisions, lifecycle and marketing-submission recommendations for AI-enabled device software, explicit attention to foundation models/LLMs, stronger expectations for data […]

Pharma companies can automate regulatory submission workflows by combining robust submission platforms, data standards (eCTD and emerging v4.0 models), modular document management, rule-based and AI-assisted validation, and tight governance. Done right, automation reduces cycle time, cuts manual errors, improves traceability, and supports audit-readiness, but success requires clear process mapping, validated tools, vendor controls, data standards […]

Module 1 for the eCTD has been updated in both the US and EU during 2024–2025 with clearer validation criteria, controlled vocabularies, and machine-readable metadata to support the gradual global shift to eCTD v4.0. EMA enforced EU M1 v3.1 validation criteria v8.0 from 1 March 2025, requiring sponsors to update submission packaging. The FDA published […]

eCTD v4.0 is a structural and data-driven upgrade to the electronic Common Technical Document, changing how dossiers are built, indexed, and delivered. Many companies are rushing to adopt it, but common errors, underestimating metadata and controlled vocabulary needs, weak migration strategies for legacy content, insufficient validation and testing, poor stakeholder governance, and vendor/tooling blind spots, […]

Regulatory intelligence, when tightly integrated with a modern quality ecosystem (digital QMS, MES, MCP, CAPA analytics, and AI), can materially reduce repeated FDA Form 483 observations by turning reactive fixes into systemic prevention. Regulatory intelligence helps teams anticipate shifting expectations, prioritize root causes, close CAPA loops, and automate evidence trails, all of which reduce the […]

Prepare as if inspections are always possible. QA teams must keep documentation current, systems validated, staff trained, and evidence traceable. Regulators are performing more unannounced checks globally, so build continuous inspection readiness across people, processes, and technology to reduce risk, speed responses, and protect patients. What Should QA Teams Prepare Before an Unannounced Inspection Occurs? […]

tl;dr: Quality audits and documentation management remain core pillars of regulatory compliance for manufacturing in life sciences (pharma, biotech, medical devices). Yet, many organisations still struggle with fragmented systems, manual collations, version-control chaos, and slow response times during inspections. The Model Context Protocol (MCP) is emerging as a key enabler that connects AI/agent workflows into […]

tl;dr: Model Context Protocol (MCP), the open standard that lets LLMs and agentic AI connect to live tools and data, is emerging as a practical, high-value lever for QA teams in life sciences to strengthen data integrity and traceability. By turning ELNs, LIMS, MES, and QMS into discoverable, auditable MCP servers, organizations can reduce manual […]

tl;dr: MCP (Model Context Protocol) is an open standard that lets AI agents access and act on enterprise data and services. In life sciences, MCP can speed drug discovery, automate workflows, and link AI assistants to lab, clinical and regulatory systems, but it also introduces unique security risks: prompt and code injection, data exfiltration of […]